Develops personalized immunotherapies for canine cancers, including adoptive cell therapy, oncolytic virotherapy, and autologous vaccine–cell therapy combinations. Offers a USDA‑approved autologous vaccine-plus-cell therapy for canine osteosarcoma to improve clinical outcomes and quality of life for dogs.